Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Top Cited Papers
- 10 November 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (32), 4105-4114
- https://doi.org/10.1200/jco.2012.47.4189
Abstract
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) –targeted drugs in patients with non–sm...Keywords
This publication has 20 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric CancerJournal of Clinical Oncology, 2011
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialThe Lancet, 2011
- Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung AdenocarcinomasThe American Journal of Pathology, 2010
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- Developing c-MET pathway inhibitors for cancer therapy: progress and challengesTrends in Molecular Medicine, 2009
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences, 2008
- The shadow of death on the MET tyrosine kinase receptorCell Death & Differentiation, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005